Abstract | PURPOSE: EXPERIMENTAL DESIGN: Athymic nude mice with established neuroblastoma xenografts were treated with daily i.p. or p.o. beta-glucan, in the presence/absence of i.v. MoAb twice a week, for 22-29 days. Serial tumor volumes and body weights were monitored. RESULTS: 3F8 plus beta-glucan produced near-complete tumor regression/disease stabilization, whereas 3F8 or beta-glucan alone did not significantly affect tumor growth. For NMB7 tumors, median survival of 3F8 plus beta-glucan group was 5.5-fold that of control groups (P < 0.001), and for LAN-1, the survival difference was 2.6-fold. Forty-seven percent of the mice with NMB7 and 18% with LAN-1 remained progression free in contrast to <3% of controls. Antitumor effect was seen at > or =40 microg of glucan dose, i.v. or p.o., and in all human neuroblastoma cell lines tested. No toxicities were noted in mice treated with either beta-glucan alone or 3F8 plus beta-glucan (4-4000 microg/dose). In contrast to anti-GD2 MoAb 3G6 ( IgM), 3F8 F(ab')(2) and MoAb 8H9 ( IgG1) did not activate complement and had no synergy with beta-glucan. Antitumor effect of 3F8 plus p.o. beta-glucan persisted after antiasialo-GM1 antibody treatment, as well as in NK-deficient host. CONCLUSIONS: p.o. 1,3-1,4-beta-glucan synergized with antitumor IgG and IgM MoAb in vivo. Because beta-glucan was well tolerated and inexpensive, its potential value in cancer therapy deserves further investigation.
|
Authors | Nai-Kong V Cheung, Shakeel Modak |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 8
Issue 5
Pg. 1217-23
(May 2002)
ISSN: 1078-0432 [Print] United States |
PMID | 12006541
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibodies, Monoclonal
- Gangliosides
- Glucans
- beta-Glucans
- beta-glucan, (1-3)(1-4)-
|
Topics |
- Administration, Oral
- Animals
- Antibodies, Monoclonal
(administration & dosage, pharmacology)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Synergism
- Gangliosides
(immunology)
- Glucans
(administration & dosage, pharmacology)
- Humans
- Injections, Intraperitoneal
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Mice, SCID
- Neoplasm Transplantation
- Neuroblastoma
(drug therapy, mortality, pathology)
- Survival Analysis
- Survival Rate
- Time Factors
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
- beta-Glucans
|